<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48603">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02473484</url>
  </required_header>
  <id_info>
    <org_study_id>2013_27</org_study_id>
    <secondary_id>2014-A00185-42</secondary_id>
    <nct_id>NCT02473484</nct_id>
  </id_info>
  <brief_title>Search of Protein Biomarkers in Order to Achieve a Molecular Classification of Gliomas</brief_title>
  <acronym>GLIOMIC</acronym>
  <official_title>Search of Protein Biomarkers in Order to Achieve a Molecular Classification of Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to classify high grade glioma by matrix-assisted laser desorption/ionization mass
      spectrometry imaging (MALDI MSI). In order to provide more specific informations for the
      diagnosis and the prognosis of high grade glioma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the correlation between the WHO classification 2007 only established standard diagnostic and classification by mass spectrometry gliomas (lipids, peptides, proteins)</measure>
    <time_frame>2.5 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Glioblastoma</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      tumoral DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        high grade glioma
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Main inclusion criteria:

          -  Patients with grade III or IV glioma newly diagnosed with histological evidence

          -  Surgical indication

          -  Tumor tissue available at biobank of Lille

          -  Men and women aged â‰¥ 18 years

          -  Informed Consent signed by the patient or his legal representative.

        Main exclusion criteria:

          -  Antecedents of other cancers except basal cell skin cancer or carcinoma in situ of
             the uterus cervix

          -  Previous history of brain radiotherapy

          -  Anti-tumor systemic treatments (chemotherapy or targeted therapy) prior to surgery of
             glioma

          -  Genetic disease that may cause brain tumor, potentially radiation-induced tumor

          -  History of degenerative neurological disease prior to diagnosis

          -  contraindication to MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilie Le RHUN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emilie LE RHUN, MD</last_name>
    <phone>+33 3 20 44 65 42</phone>
    <email>emilie.lerhun@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Le Rhun</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie Le Rhun, MD</last_name>
      <phone>320446642</phone>
      <phone_ext>+33</phone_ext>
      <email>emilie.lerhun@chru-lille.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 25, 2016</lastchanged_date>
  <firstreceived_date>June 12, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High Grade Glioma</keyword>
  <keyword>Proteomics</keyword>
  <keyword>MALDI-MSI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
